Eli Lilly Surges 6.5% on Q1 Blowout and $2 Billion Revenue Guidance Hike
Eli Lilly (LLY) shares jumped 6.55% in early Thursday trading, vastly outperforming a flat S&P 500, after the pharmaceutical giant reported first-quarter results that shattered Wall Street expectations. The rally was fueled by a massive 'beat and raise' performance, with the company hiking its full-year revenue outlook by $2 billion on the back of insatiable demand for its GLP-1 weight-loss and diabetes franchise.
GLP-1 Dominance Drives Record Revenue
Eli Lilly delivered a dominant first-quarter performance for 2026, reporting revenue of $19.8 billion. This figure represents a staggering 56% increase year-over-year and handily beat the analyst consensus of $17.62 billion. The growth was almost entirely powered by the company’s incretin franchise, which includes the blockbuster diabetes treatment Mounjaro and the weight-loss drug Zepbound.
Mounjaro sales skyrocketed 125% to $8.7 billion for the quarter, while Zepbound generated $4.16 billion, an 80% increase compared to the same period last year. These results suggest that Lilly is successfully navigating previous manufacturing bottlenecks, as volume growth of 65% more than offset a 13% decline in realized prices due to broader insurance coverage and rebates.
Earnings Shatter Estimates
On the bottom line, Lilly reported non-GAAP earnings per share (EPS) of $8.55, a 156% increase from the prior year. This result blew past the $7.06 average analyst estimate. The company’s ability to convert high-volume sales into robust profitability was a key highlight for investors, with gross margins remaining resilient at 82.6% despite pricing headwinds.
Management also highlighted the recent U.S. FDA approval of Foundayo (orforglipron), the first oral GLP-1 pill that can be taken without the strict food and water restrictions associated with older oral treatments. While still in the early stages of rollout, Foundayo is viewed by analysts as a critical third pillar in Lilly’s metabolic portfolio that could significantly expand the addressable market for weight-loss therapies.
A Massive Guidance Hike
The primary catalyst for the stock's 6.55% surge to $906.95 was a substantial upward revision to the company's full-year 2026 outlook. Lilly now expects annual revenue between $82.0 billion and $85.0 billion, up from its previous range of $80.0 billion to $83.0 billion. The company also raised its non-GAAP EPS guidance to a range of $35.50 to $37.00, compared to the prior forecast of $33.50 to $35.00.
This guidance raise signals management's confidence in sustained demand and improving supply chain dynamics. CEO David A. Ricks noted that 2026 is off to a 'strong start,' emphasizing that the company is continuing to invest heavily in manufacturing capacity and pipeline diversification, including the recent $2.3 billion acquisition of Ajax Therapeutics to bolster its oncology presence.
Market Context and Outlook
Lilly’s move today represents a sharp divergence from the broader market, with the stock’s 6.37% outperformance against the S&P 500 highlighting its status as a defensive growth leader. While the healthcare sector has faced volatility, Lilly’s execution in the obesity market continues to set it apart from peers. Analysts at several major firms, including Morgan Stanley and BMO Capital, have already begun nudging price targets higher following the report, with some suggesting the company is well-positioned to reclaim its $1 trillion market capitalization. Investors will now focus on the pace of the Foundayo launch and the company's ability to maintain its lead over rival Novo Nordisk in the increasingly competitive GLP-1 space.
Key Takeaways
- Eli Lilly shares rose 6.55% to $906.95 following a significant Q1 earnings beat and a $2 billion raise to full-year revenue guidance.
- Mounjaro and Zepbound combined for over $12.8 billion in quarterly sales, proving that demand for GLP-1 therapies remains at record levels.
- The company raised its 2026 non-GAAP EPS guidance to $35.50–$37.00, well above the previous analyst consensus of $34.39.
- The FDA approval of Foundayo, an oral weight-loss pill, provides a new long-term growth catalyst as the company expands beyond injectable treatments.